SpectRx buys Sterling Medivations for $4.4 million
This article was originally published in Clinica
Executive Summary
SpectRx has bought private insulin delivery company Sterling Medivations in a share deal worth around $4.4 million. Los Altos Hills, California-based Sterling has a range of FDA-cleared products, which SpectRx plans to launch from this year. The company also has several products in development or under review by the FDA, which should lead to new product introductions at regular intervals, SpectRx believes.